The closure of the NAVAL-1 trial and the exploration of strategic alternatives suggest that Viracta Therapeutics is considering significant changes. This could lead to mergers, acquisitions, or restructuring, impacting the company's future operations and stock price. However, the exact nature of these changes is not specified, leading to a neutral short-term impact until more details are available.